Drug for treatment of breast cystic hyperplasia disease

Abstract

A drug for treatment of breast cystic hyperplasia disease is provided; the invention relates to the drug; the invention provides the drug for treatment of breast cystic hyperplasia disease, and is characterized in that the drug is composed of the following traditional Chinese medicinal materials in parts by weight: 10-30 parts of sea clam shells, 5-15 parts of safflower, 10-30 parts of radix paeoniae rubra, 10-30 parts of cortex moutan, 10-50 parts of pollen, 5-20 parts of peach kernels, 10-30 parts of rhizoma anemarrhenae, 10-30 parts of fritillary, 10-20 parts of angelica sinensis, 10-50 parts of spica prunellae, 6-20 parts of apricot kernels, 10-30 parts of poria cocos, 10-30 parts of rhizoma atractylodis macrocephalae, 6-30 parts of cornu bubali, and 5-30 parts of cornu cervi degelatinatum. Aiming at attacking characteristics of breast cystic hyperplasia disease, the medicines capable of promoting blood circulation to remove blood stasis, clearing and activating the channels and collaterals, regulating qi and blood and invigorating spleen and soothing liver have synergistic effect, and the purpose of treatment of breast cystic hyperplasia disease through resisting degeneration, resisting proliferation, resisting fibrosis, regulating internal secretion and recovering ovarian functions is achieved.

Description

technical field [0001] The invention relates to a medicine, especially a medicine for treating breast cystic hyperplasia. Background technique [0002] Cystic hyperplasia of the breast belongs to the degeneration of mammary ducts and glandular lobules. It is a frequently occurring disease in women aged 30-50. It often involves both breasts or the whole breast, but it is rarely limited to a single breast or a certain part. The onset is related to ovarian dysfunction. , that is, the decrease of progesterone secretion is related to the relative increase of estrogen, mainly due to the cystic expansion of the duct, papillary hyperplasia of the duct epithelium and fibrous tissue hyperplasia of the lobule, and the unencapsulated cysts are of different sizes, containing yellow-green, brown , bloody colorless serous, most of which are simple cystic expansion without epithelial hyperplasia, a few with epithelial dysplasia have a certain possibility of malignant transformation, current...

AI Technical Summary

Problems solved by technology

[0002] Cystic hyperplasia of the breast belongs to the degeneration of mammary ducts and glandular lobules. It is a frequently occurring disease in women aged 30-50. It often involves both breasts or the whole breast, but it is rarely limited to a single breast or a certain part. The onset is related to ovarian dysfunction. , that is, the decrease of progesterone secretion is related to the relative increase of estrogen, mainly due to the cystic expansion of the duct, papillary hyperplasia of the duct epithelium and fibrous tissue hyperplasia of the lobule, and the unencapsulated cysts are of different sizes, containing yellow-green, brown , bloody colorless serous, most of which are simple cystic expansion without epithelial hyperplasia, a few with epithelial dysplasia have a certain possibility of malignant transformation, currently Western medicine believes that the mass increases rapidly, or the epithelial cell hyperplasia is active Surgical treatment is advocated, or the hormone testosterone propionate is used for treatment; but the effect is not ideal, and surgical treatment has a great impact on psychology and normal physiology, and most patients are unwilling to accept it. It has practical clinical significance to study Chinese herbal medicine with definite curative effect in treating breast cystic hyperplasia

Images